These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27739239)

  • 21. Prenatal diagnosis and prevalence of critical congenital heart defects: an international retrospective cohort study.
    Bakker MK; Bergman JEH; Krikov S; Amar E; Cocchi G; Cragan J; de Walle HEK; Gatt M; Groisman B; Liu S; Nembhard WN; Pierini A; Rissmann A; Chidambarathanu S; Sipek A; Szabova E; Tagliabue G; Tucker D; Mastroiacovo P; Botto LD
    BMJ Open; 2019 Jul; 9(7):e028139. PubMed ID: 31270117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fetal nuchal translucency in severe congenital heart defects: experiences in Northern Finland.
    Alanen J; Leskinen M; Sairanen M; Korpimaki T; Kouru H; Gissler M; Ryynanen M; Nevalainen J
    J Matern Fetal Neonatal Med; 2019 May; 32(9):1454-1460. PubMed ID: 29157037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prospective cohort study of fetal nuchal translucency in first-trimester and pregnancy outcome].
    Tang HR; Zhang Y; Ru T; Li J; Yang L; Xu Y; Duan HL; Wang Y; Wang Y; Hu YL; Zhang Y; Zheng MM
    Zhonghua Fu Chan Ke Za Zhi; 2020 Feb; 55(2):94-99. PubMed ID: 32146737
    [No Abstract]   [Full Text] [Related]  

  • 25. Second trimester serum predictors of congenital heart defects in pregnancies without chromosomal or neural tube defects.
    Jelliffe-Pawlowski L; Baer R; Moon-Grady AJ; Currier RJ
    Prenat Diagn; 2011 May; 31(5):466-72. PubMed ID: 21351282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
    Audibert F; Gagnon A; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prenatal and newborn screening for critical congenital heart disease: findings from a nursery.
    Johnson LC; Lieberman E; O'Leary E; Geggel RL
    Pediatrics; 2014 Nov; 134(5):916-22. PubMed ID: 25287457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with late detection of critical congenital heart disease in newborns.
    Dawson AL; Cassell CH; Riehle-Colarusso T; Grosse SD; Tanner JP; Kirby RS; Watkins SM; Correia JA; Olney RS
    Pediatrics; 2013 Sep; 132(3):e604-11. PubMed ID: 23940249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
    Spencer K; Cowans NJ; Spencer CE; Achillea N
    Prenat Diagn; 2010 Oct; 30(10):937-40. PubMed ID: 20687123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-based biomarker screening and the development of severe preeclampsia in California.
    Taché V; Baer RJ; Currier RJ; Li CS; Towner D; Waetjen LE; Jelliffe-Pawlowski LL
    Am J Obstet Gynecol; 2014 Oct; 211(4):377.e1-8. PubMed ID: 24631701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population.
    Schwärzler P; Carvalho JS; Senat MV; Masroor T; Campbell S; Ville Y
    Br J Obstet Gynaecol; 1999 Oct; 106(10):1029-34. PubMed ID: 10519427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second trimester prenatal screening for Down's syndrome in Mainland Chinese subjects using double-marker analysis of α-fetoprotein and β-human chorionic gonadotropin combined with measurement of nuchal fold thickness.
    Liu F; Liang H; Jiang X; Zhang Y; Xue L; Yang C; Cheng J; Liu P; Liu Y; Guo X
    Ann Acad Med Singap; 2011 Jul; 40(7):315-8. PubMed ID: 21870022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maternal characteristics and mid-pregnancy serum biomarkers as risk factors for subtypes of preterm birth.
    Jelliffe-Pawlowski LL; Baer RJ; Blumenfeld YJ; Ryckman KK; O'Brodovich HM; Gould JB; Druzin ML; El-Sayed YY; Lyell DJ; Stevenson DK; Shaw GM; Currier RJ
    BJOG; 2015 Oct; 122(11):1484-93. PubMed ID: 26111589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of fetal nuchal translucency (NT) and ductus venosus blood flow (DV) in the detection of congenital heart defects].
    Baś-Budecka E; Perenc M; Sieroszewski P
    Ginekol Pol; 2010 Apr; 81(4):272-6. PubMed ID: 20476599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of Behçet's disease on first and second trimester serum screening markers.
    Yılmaz ZV; Türkmen GG; Yılmaz E; Dağlar K; Kırbaş A; Sanhal C; Yücel A; Uygur D
    J Obstet Gynaecol Res; 2017 Mar; 43(3):511-515. PubMed ID: 27987350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
    Spencer K; Cowans NJ; Avgidou K; Molina F; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jan; 31(1):15-9. PubMed ID: 17999381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.